Furthermore, there is scientific evidence of the luminal subtype-specific expression pattern in luminal breast cancer tumors, as is the case for DSCAM-AS1, which is related to estrogen receptor function in breast cancer luminal cells [30], and GATA3-AS1, which has also been related to the predictive value of neoadjuvant chemotherapy [27]. This evidence concerns the gene DSCAM and breast cancer.